ABOUT THIS JOURNAL

Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci), launched in 2003, is the official journal of the Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.

SUBMISSION OF MANUSCRIPT

Manuscript should be submitted online at: http://www.cpn.or.kr/submission. If you have difficulties in submitting your manuscript electronically, please contact the Editorial Office at: webmaster@kcnp.or.kr. The receipt of the manuscript will be acknowledged by an e-mail which includes a manuscript ID number. Accepted manuscripts become the permanent property of the Korean College of Neuropsychopharmacology. They should not be republished without permission from the publisher (KCNP). The corresponding author should send a copyright transfer form in behalf of all authors after the notification of acceptance of the manuscripts.

ETHICAL CONSIDERATIONS

All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines recommended by the Council of Science Editors (http://www.councilscienceeditors.org/), International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org/), World Association of Medical Editors (WAME, http://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE). Any study including human data must be reviewed and approved by a responsible institutional review board (IRB). Papers reporting experiments involving human subjects must contain the statement that the research was approved by an Internal Review Board, Helsinki Committee or similar body and that subjects gave written informed consent. Authors must ensure that patient confidentiality is in no way breached. Do not use real names, initials, or disclose information that might identify a particular person without informed consent for publication. The editor may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents. The author clearly states that the experiments were performed in accordance with accepted guidelines such as ‘Guiding Principles in the Care and Use of Animals’ (DHEW Publication, NIH, 80-23). Animal experiments also should be reviewed by an appropriate committee (IACUC) for the care and use of animals. Also studies with pathogens requiring a high degree of biosafety should pass review of a relevant committee (IBC). Clinical Psychopharmacology and Neuroscience will follow the guidelines by the Committee on Publication Ethics (COPE, http://publicationethics.org/) for settlement of any misconduct. Any research that deals with a clinical trial should be registered with a primary national clinical trial registration site such as the Clinical Research Information Service (CRIS, https://cris.nih.go.kr), other primary national registry sites accredited by World Health Organization (https://www.who.int/ictrp/network/primary/en/) or ClinicalTrial.gov (https://clinicaltrials.gov/), a service of the US National Institutes of Health.

DATA SHARING POLICY

For clarification on data accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is mandatory when requested by reviewers. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.
AUTHORSHIP

All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author affirms that he or she had access to all data from the study, both what is reported and what is unreported, and also that he or she had complete freedom to direct its analysis and its reporting, without influence from the sponsors. The corresponding author also affirms that there was no editorial direction or censorship from the sponsors. Authorship credit should be based on: 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) drafting the work or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conditions 1, 2, 3, and 4 must ALL be met. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is also not sufficient. Only those with key responsibility for the material in the article should be listed as authors; others contributing to the work should be recognized in an Acknowledgment.

COPYRIGHT

All published papers become the permanent property of the Korean College of Neuropsychopharmacology. Copyrights of All published materials are owned by the Korean College of Neuropsychopharmacology. Permission must be obtained from the Korean College of Neuropsychopharmacology for any commercial use of materials. Authors submitting a manuscript should sign and return a completed Copyright Transfer Agreement to the editor-in-chief of the journal when the paper is accepted for publication. All authors must read and agree to the conditions outlined in the form, and must sign the form or agree that the corresponding author can sign on their behalf. Articles cannot be published until a signed form has been received. Authors can download the form from http://www.cpn.or.kr/submission/File/Copyright_form.pdf.

TYPES OF ARTICLES

Clinical Psychopharmacology and Neuroscience publishes Review Articles, Original Articles, Brief Reports, Case Reports, and Letters to the Editor.

Reviews Articles

Review Articles describe overviews on an important topic of clinical psychopharmacology and neuroscience. Reviews will be invited by the Editors but may also be submitted. Review Articles should not exceed 5,000 words (excluding references, tables, and figure legends).

Original Articles

Original Articles are papers containing results of basic or clinical investigations, which are sufficiently well documented to be acceptable to critical readers. There is no limitation in length of manuscript, but excessive illustrations and large tables are not recommended.

Brief Reports

Brief Reports contain research results corresponding to the scope of this journal. It should not exceed 1,500 words with no more than two figures or tables.

Case Reports

Case Reports deal with issues of rare cases that should be reported to other clinicians or medical researchers. Maximum length of manuscript is 1,500 words (excluding references, tables, and figure legends).
INFORMATION FOR AUTHORS

Letters to the Editor

Letters to the Editor are a comment from readers for a published article of this journal and a reply from the authors.

REVIEW PROCESS

Papers in all categories will be peer reviewed. First they are reviewed generally by editor-in-chief, given priority based on originality, significance and interest to our readers. Then manuscripts with sufficient priority are assigned to an associate editor with expertise in the subject. Associate editor allocates the manuscripts to two most relevant investigators for review of the contents. If manuscripts were judged appropriate for the publication, review for statistics may be additionally requested. Acceptance of the manuscript is decided based on the critiques and recommended decision of the reviewers. A reviewer’s decision is made as "acceptance without revision", "acceptance after minor revisions", "review again after revisions", and "rejection". The reviewed manuscripts are returned back to the corresponding author with reviewers’ comments that are judged to be useful. All reviewers remain anonymous and expected to maintain confidentiality.

MANUSCRIPT ORGANIZATION AND FORMAT

A. General guideline

1. All materials must be written in English (Microsoft Word files are preferred).
2. The manuscript should be prepared according to Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, as presented at www.icmje.org/recommendations.
3. The manuscript including tables and their footnotes, and figure legends, must be typed using double spaced, 12 point font on A4 or letter size white paper, with a margin of at least 2.5 cm on every side.
4. The manuscript should be in the following sequence: title page, abstract and keywords, introduction, methods, results, discussion, acknowledgments, references, tables, and figure legends.
5. All pages should be numbered consecutively in the upper right-corner starting from the title page.
6. Both conventional units of measure and System International (SI) units can be used, but authors must use only one type of units in an article. The metric system should be preferred for length, area, mass, and volume.
7. Use generic names of drugs, unless the specific trade name is directly relevant to the study design or discussion.
8. Do not use abbreviations in the title or abstract. Spell out all abbreviations the first time they are used. Idiosyncratic abbreviations should not be used.
9. If the manuscript is a contraction or part of a thesis for a degree, they should be acknowledged.

B. Title page

1. This should contain the title of an article, full names of authors and institutional affiliations. If several authors and institutions are listed, they should be clearly indicated with which department and institution each author is affiliated.
2. In a separate paragraph, address for correspondence, including the name of corresponding author, address (institutional affiliation, city, zip-code and country), ORCID (Open Researcher and Contributor ID), and e-mail address, should be given.
3. If the paper was presented at a meeting, it should be written including the organization, place, and date of presentation.
4. Acknowledgment of all funding support for the work should also be made on this page.
5. A running title, less than ten words, should not be declarative or interrogative sentences.

C. Abstract and keywords

1. The abstract should be less than 250 words. It should consist of four paragraphs, Objective, Methods, Results, and Conclusion, except Reviews and Case Reports.
2. Abbreviations, if needed, should be kept to absolute minimum with proper identifications. Abstracts for case report may deviate from this format, but the same restrictions of word count.
3. Up to six keywords should be listed at the bottom of abstract to be used as index terms. For the selection of keywords, refer Medical Subject Heading in Index Medicus or in internet site, https://meshb.nlm.nih.gov/search

D. Introduction
1. Brief background, references to the most pertinent papers generally enough to inform readers and relevant findings of others are described.
2. The specific question to which the authors’ particular investigation being studied, should also be described.

E. Methods
1. Explanation of the experimental methods should be concise and sufficient for repetition by other qualified investigators.
2. Procedures that have been published previously should not be described in detail. However, new or modifications of previously published procedures need full descriptions.
3. The sources of special chemicals or preparations should be given along with their location (name of company, city and state, and country).
4. Methods of statistical analyses and criteria of significance level should be described.
5. In Case Reports, case history or case description replaces the Methods section as well as Results section.
6. Studies performed using clinical samples or data must include information on the IRB approval or waiver with an approval (waiver) number, and written informed consents from the subjects. Also, studies involving animals must include information on the IACUC approval with approval number.
7. Description of participants: Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors); and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only 1 sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.

F. Results
1. This section should include a concise textual description of the data presented in tables and figures.
2. Excessive repetition of table or figure contents should be avoided.
3. Result should report test statistics (e.g., F or t value) with p values.

G. Discussion
1. The data should be interpreted concisely without repeating materials already presented in the results.
2. Speculation is permitted, but it must be supported by the presented data of authors and be well founded.

H. Acknowledgments
All persons who have made substantial contribution, but who are not eligible as authors are named in acknowledgment.

I. Conflicts of Interest
1. All potential conflicts of interest and financial support for all authors must be disclosed.
2. Conflicts of interest may involve any of the following issues: acting as a guarantor of the article; certain types of author contributions; providing financial support; having potentially competing interests.

J. Author Contributions
Authors must include a statement to specify the contributions of each co-author. The statement can be up to several sentences long, describing the specific contributions made by each author. The name of each author must appear at least once in any of the following categories; Conceptualization, Data acquisition, Formal analy-
K. References
1. We recommend the use of a tool such as EndNote or Reference Manager for reference management and formatting. EndNote reference styles can be searched for here: http://www.endnote.com/support/enstyles.asp. Reference Manager reference styles can be searched for here: http://www.refman.com/support/rmstyles.asp.
2. The Vancouver system of referencing should be used (examples are given below).
3. Citation of references in the text should be made by giving consecutive number in brackets. They should be listed in the order of citation in the text with consecutive number in this separate section.
4. In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first six followed by et al. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g., Smith A, 2000, unpublished data).
5. Names of journals should be abbreviated in the style used in Index Medicus.
6. Authors are responsible for the accuracy and completeness of their references and text citations.
7. Examples of reference style:

[Original article]
Chung IW, Kim YS, Chen G, Manji HK, Potter WZ, Pickar D. Pharmacologic profile of natural products used to treat psychotic illnesses. Psychopharmacol Bull 1995;31:139-144.

[Articles in press]

[Manual, Diagnostic Scheme, etc.]

[Book chapter]

[Book]

[Proceeding of conference]

[Electronic material]

[Unpublished work]
Unpublished work by the authors including papers submitted for publication but not yet accepted, should not be included in the list of references but referred to in the text as ‘(Jones et al. unpublished observations)’. Personal communications made in writing to the author(s) may be sparingly cited as ‘(Smith J, personal communication: June 1998)’. 
L. Tables
1. Tables should not be inserted in the appropriate place in the text but should be included at the end of the paper, each on a separate page.
2. Tables should be simple and should not duplicate information in figures.
3. Title all tables and number them with arabic numerals in the order of their citation.
4. Type each table on a separate sheet.
5. Each column of table should have an appropriate heading.
6. The significance of results should be indicated by appropriate statistical analysis.
7. Table footnotes should be indicated with superscript markings.
8. All units of measurement and concentration should be designated.
9. If a table must be continued, repeat the title on a second sheet, followed by "(cont)."
10. Use symbols by the order of a, b, c, d, and should be explained in the bottom.
11. Reproduced illustrations or tables should have permission to reproduce from the original publisher.

M. Figures
1. Figures should be submitted separately from the text of paper.
2. Legends of figures should be typed at the end of the paper with a separate page. Each figure should be understandable without reference to the text.
3. Graphics should be used only when a relevant point needs illustration.
4. Except for especially complicated drawings, which show large amounts of data, all figures are published at page or one column width.
5. When the figures are reduced to the size of a single column or of a single page width, the smallest parts of the figure must be legible.
6. Points of observations should be noted with different symbols rather than with different types of line and they can be directly shown in the body of figure or in the legend.
7. All photographs should be of the highest quality. On the back of each figure, affix a label giving the figure number, and an arrow indicating the top of the figure.
8. The KCNP assumes no responsibility for the quality of the photography as they appear in the Journal.

EDITORIAL OFFICE ADDRESS
Editorial Office, Clinical Psychopharmacology and Neuroscience
RN. 1003 Life Officetel, 40, 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea
TEL: +82-2-784-2742, FAX: +82-2-784-5542, E-mail: webmaster@kcnp.or.kr